By Jonathan Moreland, founder of Insider Insights and author of Profit From Legal Insider Trading.

NEW YORK (TheStreet) -- It is a victory for common sense. Tracking the trading behavior of company executives, directors and large shareholders in the stocks of firms they're registered in as "insiders" has proven to be profitable, according to both academic studies and (more importantly) the experience of professional investors.

Below are lists of the top 10 mainly open-market insider purchases and sales filed at the Securities and Exchange Commission Tuesday, Feb. 4, 2014, as ranked by dollar value. Please note, however, that these are only factual lists, not buy and sell recommendations. Dollar value is only one metric to assess the importance of an insider transaction, and, frankly, often not even the most important metric that determines if an insider transaction is significant.

At InsiderInsights.com, we find new investment ideas just about every day using these and more intricate insider screens to determine where we should focus our subsequent fundamental and technical analysis. And while stocks don't (or shouldn't) move up or down based on insider activity alone, insiders tend to be good indicators of when real stock-moving events like earnings surprises, corporate actions, and new products may be in the offing.

So use these regular Top Insider Trades columns as the initial research tools they are meant to be, and click the links in the tables to analyze a company's or insider's full insider history. Also feel free to contact us with any questions on our proprietary insider data, and how it is best analyzed.

<p>#:</p><p>Filer Name</p><p>Insider Titles</p><p>Company Name</p><p>Ticker</p><p>Trans<br>Type</p><p>Dollar Value</p>

1

Chiesi Farmaceutici

BO

Cornerstone Therap

CRTX

JB*

$109,651,976

2

Baupost Llc Ma

BO

Idenix Pharm

IDIX

JB*

$106,731,568

3

Lasry Marc

BO

Yrc Worldwide

YRCW

JB*

$61,999,996

4

Sanofi

BO

Regeneron Pharm

REGN

B

$59,303,100

5

Carlyle Mgt

BO

Yrc Worldwide

YRCW

JB*

$34,999,996

6

Flynn James E

BO

Dicerna Pharm

DRNA

JB*

$15,000,000

7

Coleman Daniel

CEO,DIR

KCG

KCG

JB*

$8,890,662

8

McCormack Riley

BO

Arca Biopharma

ABIO

JB*

$1,700,000

9

Haldeman Charles

DIR

KCG

KCG

B

$1,104,430

10

Loomis William

DIR

Phillips 66

PSX

B

$1,000,277

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

<p>#:</p><p>Filer Name</p><p>Insider Titles</p><p>Company Name</p><p>Ticker</p><p>Trans<br>Type</p><p>Dollar Value</p>

1

JP Morgan Inv Mgt

BO

Retailmenot

SALE

S

$19,264,152

2

Drummond David C

VP

Google

GOOG

AS

$6,966,374

3

Maddox Matt

PR,CFO,TR

Wynn Resorts

WYNN

S

$6,210,361

4

Cornelius James

DIR

Bristol Myers

BMY

S

$4,890,000

5

Daniel V Tierney Tr

BO

KCG

KCG

S

$4,693,828

6

Elfers Jane T

CEO,DIR

Childrens Place

PLCE

AS

$2,462,259

7

Wang Feng Ming

CEO,DIR

Ambarella

AMBA

AS

$2,262,965

8

Miller Robert Jos

DIR

Wynn Resorts

WYNN

S

$2,154,555

9

Peake Adam

VP,SO

Under Armour

UA

S

$2,136,000

10

Atchison James

DIR

Seaworld Ent

SEAS

AS

$1,577,451

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes

Jonathan Moreland is the founder of

InsiderInsights.com, which produces a weekly newsletter and offers professional screening and alerting tools to analyze a proprietary, real-time insider data feed. He is also the principal of Insider Asset Management, a registered investment adviser in New York. Mr. Moreland has been analyzing insider data professionally for two decades and has been a contributor to TheStreet.com since 2001. A fundamental analyst with an MBA in finance, Mr. Moreland long ago identified insider data as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis and stock recommendations stemming from it. He is also author of

Profit From Legal Insider Trading

.

Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. While he cannot provide investment advice or recommendations, Moreland appreciates your feedback;

click here

to send him an email.